… The expression of epidermal growth factor (EGF) receptor (P = 0.037),transforming growth
factor α (TGF-α; P < 0.001), and HER2 (P = 0.066;positive trend) correlated with activation of …

… inhibitors gefitinib and erlotinib and the mAb cetuximab, which are approved for treatment of
a … In this study, we have investigated EGFR inhibition as a therapeutic option in the treatment …

… epidermal growth factor receptor (EGFR/ErbB1/HER1) belongs to the ErbB/HER-family of
tyrosine kinase receptors … -derivative able to bind and block the TK residues of EGFR, VEGFR2 …

… and the frequent expression of HER2 have made these receptors targets for therapy in
pancreatic cancer [34,35]. In general, EGFR inhibitors have yielded modest effectiveness in tumor …

… Growth factors are locally-derived peptide hormones which are involved in regulating … The
design of anticancer therapies using a selective EGFR inhibitor was proposed by Mendelsohn …

… should affect the clinical response to EGFR inhibition. To define the usefulness of KRAS
mutations as a predictor of response to anti-EGFR therapy, Lievre et al screened tumors from 30 …

… patients who responded to gefitinib derived substantial benefit from the therapy, with a median
… appears to be a mechanistic effect of EGFR inhibition in the skin. The correlation between …

… EGFR inhibition in second-line therapy of mCRC patients after progression from first-line
treatment … Third-line treatment in patients with RAS WT mCRC who obtained a PR/CR in first …

… therapies for patients harboring EGFR gene alterations. Conversely, clinical implementation
of EGFR inhibitors … autocrine or paracrine growth factors that are derived from cancer cells or …

… In the present study, we hypothesized that the use of EGFR inhibitors for cancer therapies in
… Lung tissue sections obtained from mice 21 days after treatment with either bleomycin and …